SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3102>> another Jakafi whiff in cancer << Can you refresh my memory re. scaram(o)uche11/28/2016
3101So, another Jakafi whiff in cancer. Given the magnitude of the INCY's slidetuck-1/28/2016
3100baricitinib NDA submitted.scaram(o)uche11/19/2016
3099Merck buys IOmet. iometpharma.comscaram(o)uche-1/11/2016
3098GILD vs. INCY, round four.....scaram(o)uche-12/18/2015
3097Would have loved to be a fly on the wall in the due diligence discussions with GBiotech Jim112/17/2015
3096Haven't seen any mention of YMI in any of today's PRs covering the Galapscaram(o)uche-12/17/2015
3095Haven't seen new data, so don't know if this is a discussion of past stuscaram(o)uche-11/12/2015
3094Pfizer gets a complete response letter for tofacitinib, moderate to severe chronscaram(o)uche-10/14/2015
3093PGS on RA-BEAM: siliconinvestor.comDewDiligence_on_SI-10/14/2015
3092All four trials now in, not much detail here..... Baricitinib Demonstrates Supescaram(o)uche-10/14/2015
3091pointer from Ozgur Ogut.... clinicaltrials.gov (fully enrolled)scaram(o)uche-10/9/2015
3090ex-poor grad student on the breakup...... ozgurogut.com way at the bottom.....scaram(o)uche-9/29/2015
3089Baricitinib Superior to Methotrexate in Reducing Signs and Symptoms in Pivotal Pscaram(o)uche-9/29/2015
3088so thats the reason they discontinue the collaboration with galapagos and their dalroi-9/26/2015
3087>> we will advance ABT-494 to Phase 3 studies with a once-daily formulatioscaram(o)uche-9/25/2015
3086AbbVie to Advance Once-Daily ABT-494 to Phase 3 in Rheumatoid Arthritis by Year-scaram(o)uche-9/25/2015
3085AbbVie's ABT-494 Meets Primary Endpoint in Two Phase 2 Studies in Rheumatoidscaram(o)uche-9/25/2015
3084Just noting the occasion, rumors, rumors, rumors...... finance.yahoo.com{"scaram(o)uche-9/10/2015
3083Anyone seen the Cowen report where they discuss the INCY IDO inhibitor data in aBiotech Jim-8/17/2015
3082So the IDO/ipi data will mature around May of next year, per clinicaltrials.gov.tuck-8/4/2015
3081(snip) Product Update Jakafi (ruxolitinib) – JAK1 and JAK2 Inhibitor Follow-uscaram(o)uche-8/4/2015
3080Baracitinib at ADA: Baracitinib in Diabetic Kidney Disease: P2 ADA abstracts otuck-5/14/2015
3079Anyone know if the management said something about updated P2 data for Yervoy/INtuck-5/14/2015
3078Thanks for posting this link, Rick. I am impressed by the results. r/r cHL (Biotech Jim-5/13/2015
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News